Bottom line
Is BBH a good fund? The bottom line
BBH is a managed technology sector ETF from VanEck.
It charges 0.35% — about $35 a year on every $10,000 invested, cheaper than 90% of technology sector funds we track.
It returned +21.2% over one year, +2.7% a year over five years, +4.5% a year over ten (as of Dec 31, 2025, per its prospectus).
With $396 million in net assets and 25 holdings, its largest position is Amgen Inc (15.2%) and the top 10 make up 70.3% of the portfolio.
The closest lower-cost alternative we found is IBBQ (0.19%, 59% top-holdings overlap).
What stands out
- Low cost: cheaper than 90% of technology sector peers
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 70.3% of assets
Updated Nov 19, 2026
What BBH invests in
VanEck Biotech ETF (the Fund) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (the Biotech Index or the Index).
The Fund normally invests at least 80% of its total assets in securities that comprise the Funds benchmark index. For purposes of this policy, the term assets means net assets plus the amount of any borrowings for investment purposes. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Biotech Index, companies must generate at least 50% of their revenues from biotechnology. Biotechnology includes companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies). Of the largest 50 stocks in the biotechnology industry…
From the fund's prospectus (filed Jan 27, 2026).
BBH performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BBH | +21.2% | +2.7% | +4.5% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What BBH costs
On a $10,000 investment, BBH's 0.35% expense ratio costs about $35 a year. The prospectus estimates $443 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
BBH top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Amgen Inc | 15.25% |
| 2 | Gilead Sciences Inc | 12.79% |
| 3 | Vertex Pharmaceuticals Inc | 9.10% |
| 4 | Regeneron Pharmaceuticals Inc | 6.21% |
| 5 | Revolution Medicines Inc | 5.27% |
| 6 | Argenx SE | 4.97% |
| 7 | Natera Inc | 4.92% |
| 8 | IQVIA Holdings Inc | 4.31% |
| 9 | Alnylam Pharmaceuticals Inc | 3.83% |
| 10 | Biogen Inc | 3.63% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 70.3% of the fund. See all top 25 holdings and asset mix →